ArticleThe clinical respiratory journal2025
High Circulating Platelet Count as a Risk Factor for Lung Squamous Cell Carcinoma: A Retrospective Study and Mendelian Randomization Analysis.
Article in The clinical respiratory journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThe association between platelet count (PLTC) and the risk of lung squamous cell carcinoma (LUSC) remains unclear.
methodsWe analyzed 19 223 samples from public and internal cohorts to investigate the relationship between high PLTC and the risk of developing LUSC using the retrospective analysis and Mendelian randomization analysis (MRA).
resultsElevated PLTC were detected in the population with lung cancer compared to healthy individuals (odds ratio [OR] = 1.41 [per 1-SD], 95% CI 1.13-1.75, p < 0.05). Furthermore, there is a significant association between elevated PLTC and an increased risk of LUSC based on an in-house cohort (OR = 1.63 [per 1-SD], 95% CI 1.08-2.45, p < 0.05). Individuals with high PLTC had an increased risk of developing LUSC using the inverse-variance weighting method (OR = 1.62 [per 1-SD], 95% CI 1.14-2.31, p < 0.05), an outcome that was directionally consistent across the weighted median, MR Egger, simple mode, and weighted modes methods (OR > 1.00). No pleiotropy (the MRA pleiotropy residual sum and outlier test p = 0.553) or heterogeneity (Cochran's Q statistic p = 0.777) was found in the MRAs. Besides PLTC, age and five other hematological parameters (e.g., red blood cell count) were identified as independent factors associated with the incidence of lung cancer or its subtype LUSC (p < 0.05).
conclusionsHigh circulating PLTC may serve as a risk factor for lung squamous cell carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.